Oculoplasty and Oncology Services (Dr. Rajendra Prasad Centre for Ophthalmic Sciences), All India Institute of Medical Sciences, New Delhi, India.
Department of Ocular Pathology (Dr Rajendra Prasad Centre of Ophthalmic Sciences), All India Institute of Medical Sciences, New Delhi, India.
Indian J Ophthalmol. 2024 Oct 1;72(10):1442-1447. doi: 10.4103/IJO.IJO_3332_23. Epub 2024 Sep 27.
The coronavirus disease 2019 (COVID-19) pandemic led to overall interrupted medical care, resulting in disease progression and morbidity. The study aimed to evaluate clinicopathological presentations and severity of eyelid malignancy during the COVID era, comparing the results with patients presented during pre-COVID era and evaluating the reasons for delayed presentation in patients with advanced eyelid malignancy in the COVID-era.
This was a comparative, ambispective observational study. Data regarding demographic, clinical, histopathology, and treatment modalities of confirmed cases of eyelid malignancy admitted during the period from March 2020 to September 2022 (defined as COVID era group) were collected and compared with retrospectively collected data from March 2017 to March 2020 (defined as pre-COVID era group). COVID era patients were further categorized as localized and advanced disease. Patients with advanced eyelid malignancy during COVID era were further subjected to a questionnaire to evaluate the reasons for delayed presentation.
In total, 115 patients of eyelid malignancy were studied [COVID era group 40 (35%) and pre-COVID era group 75 (65%)]. A statistically significant increase in the duration of disease (P = 0.0001) and advanced tumor T-stage (P = 0.03) was noticed in the COVID era group. Demographic, histopathology, and ocular morbidity details were similar in both groups. The common reasons that led to delay in presentation and treatment in advanced T-stage patients during the COVID era were fear of acquiring COVID, lockdown, and lack of medical facilities.
During the COVID-19 pandemic, both hospital- and patient-related factors contributed to delay in presentation, leading to advanced-stage disease indicating need of triaging of eyelid malignancy in the event of such pandemics in future.
2019 年冠状病毒病（COVID-19）大流行导致整体医疗服务中断，导致疾病进展和发病率上升。本研究旨在评估 COVID 时代眼睑恶性肿瘤的临床病理表现和严重程度，将结果与 COVID 前时代的患者进行比较，并评估 COVID 时代晚期眼睑恶性肿瘤患者就诊延迟的原因。
这是一项比较性、前瞻性观察研究。收集了 2020 年 3 月至 2022 年 9 月期间（定义为 COVID 时代组）确诊的眼睑恶性肿瘤患者的人口统计学、临床、组织病理学和治疗方式数据，并与 2017 年 3 月至 2020 年 3 月（定义为 COVID 前时代组）回顾性收集的数据进行比较。将 COVID 时代的患者进一步分为局限性疾病和晚期疾病。对 COVID 时代患有晚期眼睑恶性肿瘤的患者进行问卷调查，以评估就诊延迟的原因。
共研究了 115 例眼睑恶性肿瘤患者[COVID 时代组 40 例（35%）和 COVID 前时代组 75 例（65%）]。COVID 时代组疾病持续时间（P = 0.0001）和晚期肿瘤 T 分期（P = 0.03）显著增加。两组的人口统计学、组织病理学和眼部发病率细节相似。COVID 时代晚期 T 期患者就诊和治疗延迟的常见原因是担心感染 COVID-19、封锁和缺乏医疗设施。
在 COVID-19 大流行期间，医院和患者相关因素都导致了就诊延迟，导致疾病进入晚期，这表明在未来发生此类大流行时需要对眼睑恶性肿瘤进行分诊。
